Treatment of six non-active secondary progressive MS patients with nasal anti-CD3 monoclonal antibody (Foralumab): safety, biomarker, and disability outcomesTanuja Chitnis,Tarun Singhal,Jonathan Zurawski,Taylor Saraceno,Thais Moreira, Tzu-Ying Chuang,Danielle Howard, John Sullivan,Shrishti Saxena,Hrishikesh Lokhande,Clare Baecher-Allan, Nancy Clementi,Howard WeinerMULTIPLE SCLEROSIS JOURNAL（2023）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
